Onconetix (ONCO) Competitors $3.65 -0.47 (-11.41%) Closing price 04:00 PM EasternExtended Trading$3.55 -0.10 (-2.82%) As of 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ONCO vs. PRPH, LPTX, MTEX, LEXX, AYTU, ABP, CLRB, NAII, EDSA, and NRSNShould you be buying Onconetix stock or one of its competitors? The main competitors of Onconetix include ProPhase Labs (PRPH), Leap Therapeutics (LPTX), Mannatech (MTEX), Lexaria Bioscience (LEXX), Aytu BioPharma (AYTU), Abpro (ABP), Cellectar Biosciences (CLRB), Natural Alternatives International (NAII), Edesa Biotech (EDSA), and NeuroSense Therapeutics (NRSN). These companies are all part of the "pharmaceutical products" industry. Onconetix vs. Its Competitors ProPhase Labs Leap Therapeutics Mannatech Lexaria Bioscience Aytu BioPharma Abpro Cellectar Biosciences Natural Alternatives International Edesa Biotech NeuroSense Therapeutics ProPhase Labs (NASDAQ:PRPH) and Onconetix (NASDAQ:ONCO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations. Which has higher valuation & earnings, PRPH or ONCO? ProPhase Labs has higher revenue and earnings than Onconetix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProPhase Labs$6.77M3.23-$53.36M-$1.26-0.42Onconetix$1.33M4.25-$58.69MN/AN/A Is PRPH or ONCO more profitable? ProPhase Labs has a net margin of 0.00% compared to Onconetix's net margin of -3,327.03%. Onconetix's return on equity of -192.74% beat ProPhase Labs' return on equity.Company Net Margins Return on Equity Return on Assets ProPhase LabsN/A -262.42% -76.48% Onconetix -3,327.03%-192.74%-89.55% Which has more volatility and risk, PRPH or ONCO? ProPhase Labs has a beta of -0.62, suggesting that its stock price is 162% less volatile than the S&P 500. Comparatively, Onconetix has a beta of 3.39, suggesting that its stock price is 239% more volatile than the S&P 500. Does the media refer more to PRPH or ONCO? In the previous week, ProPhase Labs and ProPhase Labs both had 2 articles in the media. Onconetix's average media sentiment score of 0.95 beat ProPhase Labs' score of 0.00 indicating that Onconetix is being referred to more favorably in the news media. Company Overall Sentiment ProPhase Labs Neutral Onconetix Positive Do institutionals and insiders believe in PRPH or ONCO? 9.5% of ProPhase Labs shares are held by institutional investors. Comparatively, 23.9% of Onconetix shares are held by institutional investors. 9.6% of ProPhase Labs shares are held by company insiders. Comparatively, 3.1% of Onconetix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend PRPH or ONCO? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SummaryProPhase Labs and Onconetix tied by winning 5 of the 10 factors compared between the two stocks. Get Onconetix News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ONCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONCO vs. The Competition Export to ExcelMetricOnconetixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.64M$3.32B$6.01B$10.23BDividend YieldN/A2.29%5.66%4.69%P/E RatioN/A22.1185.3526.57Price / Sales4.25416.63582.95179.01Price / CashN/A47.1938.3262.20Price / Book0.3310.2112.726.53Net Income-$58.69M-$52.40M$3.30B$275.87M7 Day Performance16.99%0.90%1.07%-1.40%1 Month Performance32.73%12.36%7.61%5.16%1 Year Performance-99.17%30.17%79.71%31.51% Onconetix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCOOnconetix1.1451 of 5 stars$3.65-11.4%N/A-99.0%$5.64M$1.33M0.0012Analyst ForecastPRPHProPhase Labs0.369 of 5 stars$0.46+4.6%N/A-77.7%$19.02M$5.59M-0.36130Analyst ForecastLPTXLeap Therapeutics2.5348 of 5 stars$0.45+26.2%$3.38+643.4%-70.9%$18.81MN/A-0.2940News CoverageAnalyst ForecastGap DownHigh Trading VolumeMTEXMannatech1.1054 of 5 stars$9.89+16.2%N/A+10.4%$18.79M$117.87M-4.85250Analyst ForecastGap UpHigh Trading VolumeLEXXLexaria Bioscience2.8243 of 5 stars$0.95-3.1%$4.00+319.9%-70.0%$18.64M$460K-1.427News CoverageAnalyst ForecastGap DownHigh Trading VolumeAYTUAytu BioPharma3.7502 of 5 stars$1.88+9.9%$9.17+387.6%+14.1%$18.63M$66.38M-0.67160Positive NewsABPAbpro3.2677 of 5 stars$0.22-12.7%$4.00+1,684.1%N/A$17.97M$183K0.0015Analyst ForecastCLRBCellectar Biosciences2.3883 of 5 stars$5.60+3.5%$375.00+6,596.4%-92.2%$17.86MN/A-0.2810Analyst ForecastNAIINatural Alternatives International1.2622 of 5 stars$2.84-2.6%N/A-40.8%$17.51M$125.48M-1.25290Analyst ForecastGap DownEDSAEdesa Biotech3.1832 of 5 stars$2.47+0.8%$5.00+102.4%-37.7%$17.39MN/A-1.8720Positive NewsAnalyst ForecastGap DownHigh Trading VolumeNRSNNeuroSense Therapeutics2.2685 of 5 stars$1.25flat$14.00+1,020.0%+2.2%$17.08MN/A-2.3110Analyst ForecastGap Up Related Companies and Tools Related Companies PRPH Alternatives LPTX Alternatives MTEX Alternatives LEXX Alternatives AYTU Alternatives ABP Alternatives CLRB Alternatives NAII Alternatives EDSA Alternatives NRSN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONCO) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenIf you're a futures trader (or want to be one), this could be the biggest shift you'll ever see in the prop fi...Neuro Street Trading Academy | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredU.S. Government Sparking Crypto RallyAltcoin ETFs could surge prices (do this now) My "Crypto Bull Run Millionaire Blueprint" breaks down exactl...Crypto 101 Media | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Onconetix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Onconetix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
